vs
Turning Point Brands, Inc.（TPB）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
VERACYTE, INC.的季度营收约是Turning Point Brands, Inc.的1.1倍（$139.1M vs $121.0M），VERACYTE, INC.净利率更高（20.6% vs 6.8%，领先13.9%），Turning Point Brands, Inc.同比增速更快（29.2% vs 21.5%），过去两年Turning Point Brands, Inc.的营收复合增速更高（20.7% vs 10.2%）
Turning Point Australia（TPAUS）是一家位于澳大利亚的保守派游说团体，隶属于美国转折点组织但保持独立运营，由乔尔·贾马尔创立并于2023年完成注册。该团体目前正积极行动，试图影响2026年3月举行的南澳大利亚州选举结果。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
TPB vs VCYT — 直观对比
营收规模更大
VCYT
是对方的1.1倍
$121.0M
营收增速更快
TPB
高出7.7%
21.5%
净利率更高
VCYT
高出13.9%
6.8%
两年增速更快
TPB
近两年复合增速
10.2%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $121.0M | $139.1M |
| 净利润 | $8.2M | $28.7M |
| 毛利率 | 55.9% | 72.7% |
| 营业利润率 | 16.5% | 16.3% |
| 净利率 | 6.8% | 20.6% |
| 营收同比 | 29.2% | 21.5% |
| 净利润同比 | 239.8% | — |
| 每股收益（稀释后） | $0.40 | $0.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收TPBVCYT
| Q1 26 | — | $139.1M | ||
| Q4 25 | $121.0M | $140.6M | ||
| Q3 25 | $119.0M | $131.9M | ||
| Q2 25 | $116.6M | $130.2M | ||
| Q1 25 | $106.4M | $114.5M | ||
| Q4 24 | $93.7M | $118.6M | ||
| Q3 24 | $90.7M | $115.9M | ||
| Q2 24 | $93.2M | $114.4M |
净利润TPBVCYT
| Q1 26 | — | $28.7M | ||
| Q4 25 | $8.2M | $41.1M | ||
| Q3 25 | $21.1M | $19.1M | ||
| Q2 25 | $14.5M | $-980.0K | ||
| Q1 25 | $14.4M | $7.0M | ||
| Q4 24 | $2.4M | $5.1M | ||
| Q3 24 | $12.4M | $15.2M | ||
| Q2 24 | $13.0M | $5.7M |
毛利率TPBVCYT
| Q1 26 | — | 72.7% | ||
| Q4 25 | 55.9% | 72.5% | ||
| Q3 25 | 59.2% | 69.2% | ||
| Q2 25 | 57.1% | 69.0% | ||
| Q1 25 | 56.0% | 69.5% | ||
| Q4 24 | 56.0% | 66.4% | ||
| Q3 24 | 55.6% | 68.2% | ||
| Q2 24 | 54.1% | 68.1% |
营业利润率TPBVCYT
| Q1 26 | — | 16.3% | ||
| Q4 25 | 16.5% | 26.4% | ||
| Q3 25 | 21.8% | 17.4% | ||
| Q2 25 | 22.6% | -4.0% | ||
| Q1 25 | 21.8% | 2.5% | ||
| Q4 24 | 19.1% | 3.5% | ||
| Q3 24 | 22.9% | 10.4% | ||
| Q2 24 | 24.5% | 4.0% |
净利率TPBVCYT
| Q1 26 | — | 20.6% | ||
| Q4 25 | 6.8% | 29.3% | ||
| Q3 25 | 17.7% | 14.5% | ||
| Q2 25 | 12.4% | -0.8% | ||
| Q1 25 | 13.5% | 6.2% | ||
| Q4 24 | 2.6% | 4.3% | ||
| Q3 24 | 13.6% | 13.1% | ||
| Q2 24 | 14.0% | 5.0% |
每股收益（稀释后）TPBVCYT
| Q1 26 | — | $0.35 | ||
| Q4 25 | $0.40 | $0.50 | ||
| Q3 25 | $1.13 | $0.24 | ||
| Q2 25 | $0.79 | $-0.01 | ||
| Q1 25 | $0.79 | $0.09 | ||
| Q4 24 | $0.15 | $0.07 | ||
| Q3 24 | $0.68 | $0.19 | ||
| Q2 24 | $0.68 | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $222.8M | $439.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $372.0M | $1.3B |
| 总资产 | $763.8M | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资TPBVCYT
| Q1 26 | — | $439.1M | ||
| Q4 25 | $222.8M | $362.6M | ||
| Q3 25 | $201.2M | $315.6M | ||
| Q2 25 | $109.9M | $219.5M | ||
| Q1 25 | $99.6M | $186.1M | ||
| Q4 24 | $48.9M | $239.1M | ||
| Q3 24 | $33.6M | $274.1M | ||
| Q2 24 | $142.2M | $235.9M |
股东权益TPBVCYT
| Q1 26 | — | $1.3B | ||
| Q4 25 | $372.0M | $1.3B | ||
| Q3 25 | $358.2M | $1.3B | ||
| Q2 25 | $224.8M | $1.2B | ||
| Q1 25 | $203.4M | $1.2B | ||
| Q4 24 | $190.4M | $1.2B | ||
| Q3 24 | $185.7M | $1.2B | ||
| Q2 24 | $172.8M | $1.1B |
总资产TPBVCYT
| Q1 26 | — | $1.4B | ||
| Q4 25 | $763.8M | $1.4B | ||
| Q3 25 | $742.8M | $1.4B | ||
| Q2 25 | $595.8M | $1.3B | ||
| Q1 25 | $564.6M | $1.3B | ||
| Q4 24 | $493.4M | $1.3B | ||
| Q3 24 | $488.0M | $1.3B | ||
| Q2 24 | $591.6M | $1.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $24.9M | $35.2M |
| 自由现金流经营现金流 - 资本支出 | $21.5M | — |
| 自由现金流率自由现金流/营收 | 17.8% | — |
| 资本支出强度资本支出/营收 | 2.8% | — |
| 现金转化率经营现金流/净利润 | 3.03× | 1.23× |
| 过去12个月自由现金流最近4个季度 | $43.8M | — |
8季度趋势，按日历期对齐
经营现金流TPBVCYT
| Q1 26 | — | $35.2M | ||
| Q4 25 | $24.9M | $52.6M | ||
| Q3 25 | $3.3M | $44.8M | ||
| Q2 25 | $11.8M | $33.6M | ||
| Q1 25 | $17.4M | $5.4M | ||
| Q4 24 | $17.7M | $24.5M | ||
| Q3 24 | $13.2M | $30.0M | ||
| Q2 24 | $13.4M | $29.6M |
自由现金流TPBVCYT
| Q1 26 | — | — | ||
| Q4 25 | $21.5M | $48.8M | ||
| Q3 25 | $-721.0K | $42.0M | ||
| Q2 25 | $7.8M | $32.3M | ||
| Q1 25 | $15.2M | $3.5M | ||
| Q4 24 | $16.6M | $20.4M | ||
| Q3 24 | $12.6M | $27.7M | ||
| Q2 24 | $10.9M | $26.8M |
自由现金流率TPBVCYT
| Q1 26 | — | — | ||
| Q4 25 | 17.8% | 34.7% | ||
| Q3 25 | -0.6% | 31.8% | ||
| Q2 25 | 6.7% | 24.8% | ||
| Q1 25 | 14.3% | 3.1% | ||
| Q4 24 | 17.8% | 17.2% | ||
| Q3 24 | 13.9% | 23.9% | ||
| Q2 24 | 11.7% | 23.4% |
资本支出强度TPBVCYT
| Q1 26 | — | — | ||
| Q4 25 | 2.8% | 2.7% | ||
| Q3 25 | 3.4% | 2.1% | ||
| Q2 25 | 3.4% | 1.0% | ||
| Q1 25 | 2.1% | 1.6% | ||
| Q4 24 | 1.2% | 3.5% | ||
| Q3 24 | 0.7% | 1.9% | ||
| Q2 24 | 2.7% | 2.4% |
现金转化率TPBVCYT
| Q1 26 | — | 1.23× | ||
| Q4 25 | 3.03× | 1.28× | ||
| Q3 25 | 0.16× | 2.34× | ||
| Q2 25 | 0.82× | — | ||
| Q1 25 | 1.21× | 0.76× | ||
| Q4 24 | 7.34× | 4.80× | ||
| Q3 24 | 1.07× | 1.98× | ||
| Q2 24 | 1.03× | 5.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
TPB
| US | $111.5M | 92% |
| Non Us | $9.6M | 8% |
VCYT
| Testing revenue | $135.1M | 97% |
| Product revenue | $3.7M | 3% |
| Biopharmaceutical and other revenue | $301.0K | 0% |
